Portolan Capital Management’s PureTech Health PRTC Stock Holding History

Portolan Capital Management’s Portfolio PRTC Stock Details PRTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,795	Closed	-$479K	–	148
2025 Q2	$479K	Buy	27,795 +15,910	+134%	+$280K	0.03%	115
2025 Q1	$235K	Buy	+11,885	New	+$217K	0.02%	109
2022 Q1	–	Sell	-5,749	Closed	-$213K	–	165
2021 Q4	$213K	Sell	5,749 -46,672	-89%	-$2.06M	0.01%	130
2021 Q3	$2.52M	Buy	+52,421	New	+$2.55M	0.18%	112

Other funds holding PRTC

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Portolan Capital Management's PRTC Position: Q3 2025 in Review

Portolan Capital Management sold out of PureTech Health (PRTC) in Q3 2025, closing a stake of 27,795 shares — an estimated $479K sold.

Portolan Capital Management first reported a position in PRTC in Q3 2021 and held it in 4 quarters. The position peaked at $2.52M in Q3 2021. 6 funds tracked by Wall St. Rank hold PRTC as of Q3 2025.

Portolan Capital Management reported no remaining PureTech Health position as of Q3 2025 after selling out during the quarter.
Portolan Capital Management sold 27,795 PureTech Health shares in Q3 2025, an estimated $479K.
Portolan Capital Management first reported a position in PureTech Health in Q3 2021 and held it in 4 quarters.
Portolan Capital Management's PureTech Health position peaked at $2.52M in Q3 2021.
6 funds tracked by Wall St. Rank held PureTech Health as of Q3 2025.

Based on Portolan Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.